AU2020253042B2 - Prescription of remote patient management based on biomarkers - Google Patents

Prescription of remote patient management based on biomarkers

Info

Publication number
AU2020253042B2
AU2020253042B2 AU2020253042A AU2020253042A AU2020253042B2 AU 2020253042 B2 AU2020253042 B2 AU 2020253042B2 AU 2020253042 A AU2020253042 A AU 2020253042A AU 2020253042 A AU2020253042 A AU 2020253042A AU 2020253042 B2 AU2020253042 B2 AU 2020253042B2
Authority
AU
Australia
Prior art keywords
days
probnp
level
fragment
proadm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020253042A
Other languages
English (en)
Other versions
AU2020253042A1 (en
Inventor
Stefan Gehrig
Jan Kunde
Friedrich Köhler
Tobias STUBBE
Jan Wiemer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BRAHMS GmbH
Original Assignee
BRAHMS GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP19166382.2A external-priority patent/EP3715851A1/en
Application filed by BRAHMS GmbH filed Critical BRAHMS GmbH
Publication of AU2020253042A1 publication Critical patent/AU2020253042A1/en
Application granted granted Critical
Publication of AU2020253042B2 publication Critical patent/AU2020253042B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/70—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving creatine or creatinine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Peptides Or Proteins (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
AU2020253042A 2019-03-29 2020-03-27 Prescription of remote patient management based on biomarkers Active AU2020253042B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP19166425.9 2019-03-29
EP19166382.2A EP3715851A1 (en) 2019-03-29 2019-03-29 Prescription of remote patient management based on biomarkers
EP19166382.2 2019-03-29
EP19166425 2019-03-29
EP19175720.2 2019-05-21
EP19175720 2019-05-21
PCT/EP2020/058700 WO2020201078A1 (en) 2019-03-29 2020-03-27 Prescription of remote patient management based on biomarkers

Publications (2)

Publication Number Publication Date
AU2020253042A1 AU2020253042A1 (en) 2021-06-17
AU2020253042B2 true AU2020253042B2 (en) 2025-10-02

Family

ID=69941398

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020253042A Active AU2020253042B2 (en) 2019-03-29 2020-03-27 Prescription of remote patient management based on biomarkers

Country Status (8)

Country Link
US (2) US12442825B2 (https=)
EP (1) EP3948301A1 (https=)
JP (2) JP7575400B2 (https=)
CN (1) CN113348368A (https=)
AU (1) AU2020253042B2 (https=)
BR (1) BR112021019479A2 (https=)
CA (3) CA3281050A1 (https=)
WO (1) WO2020201078A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11783944B2 (en) * 2019-09-09 2023-10-10 Neal F. Krouse System for live monitoring of vitals for patients and physicians
WO2022101937A1 (en) * 2020-11-12 2022-05-19 Shah Komal An integrated health data capture and analysis based device for evaluation, diagnosis and prognosis of heart failure
WO2022164724A1 (en) * 2021-01-27 2022-08-04 Verantos, Inc. High validity real-world evidence study with deep phenotyping
WO2022245405A1 (en) 2021-05-17 2022-11-24 Verantos, Inc. System and method for term disambiguation
US20240120105A1 (en) * 2022-10-09 2024-04-11 Morteza Naghavi Predicting adverse health risk based on ct scan images and ai-enabled cardiovascular structure volumetry
WO2025097159A1 (en) * 2023-11-05 2025-05-08 3Ive Labs, Llc Urinary oxygen and uses thereof in adaptive therapies for kidney function

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3943918A (en) 1971-12-02 1976-03-16 Tel-Pac, Inc. Disposable physiological telemetric device
US4121573A (en) 1973-10-04 1978-10-24 Goebel Fixture Co. Wireless cardiac monitoring system and electrode-transmitter therefor
FR2570703B1 (fr) 1984-09-26 1988-07-08 Commissariat Energie Atomique Complexes macropolycycliques de terres rares et application a titre de marqueurs fluorescents
US4827943A (en) 1986-09-23 1989-05-09 Advanced Medical Technologies, Inc. Portable, multi-channel, physiological data monitoring system
US4784162A (en) 1986-09-23 1988-11-15 Advanced Medical Technologies Portable, multi-channel, physiological data monitoring system
US4882733A (en) 1987-03-13 1989-11-21 Ford Aerospace Corporation Method and apparatus for combining encoding and modulation
US5511553A (en) 1989-02-15 1996-04-30 Segalowitz; Jacob Device-system and method for monitoring multiple physiological parameters (MMPP) continuously and simultaneously
US5307818A (en) 1989-02-15 1994-05-03 Jacob Segalowitz Wireless electrocardiographic and monitoring system and wireless electrode assemblies for same
US4981141A (en) 1989-02-15 1991-01-01 Jacob Segalowitz Wireless electrocardiographic monitoring system
US5168874A (en) 1989-02-15 1992-12-08 Jacob Segalowitz Wireless electrode structure for use in patient monitoring system
FR2664699B1 (fr) 1990-07-13 1995-08-18 Cis Bio Int Procede d'amplification du signal d'emission d'un compose luminescent.
US5353793A (en) 1991-11-25 1994-10-11 Oishi-Kogyo Company Sensor apparatus
US5214939A (en) 1991-11-25 1993-06-01 Carrier Corporation Variable area refrigerant expansion device having a flexible orifice
ES2155068T3 (es) 1992-04-03 2001-05-01 Micromedical Ind Ltd Sistema de supervision fisiologica.
US5522396A (en) 1992-05-12 1996-06-04 Cardiac Telecom Corporation Method and system for monitoring the heart of a patient
JP2774769B2 (ja) 1993-04-26 1998-07-09 賢治 寒川 アドレノメデュリン
US5544661A (en) 1994-01-13 1996-08-13 Charles L. Davis Real time ambulatory patient monitor
DE19847690A1 (de) 1998-10-15 2000-04-20 Brahms Diagnostica Gmbh Verfahren und Substanzen für die Diagnose und Therapie von Sepsis und sepsisähnlichen systemischen Infektionen
US6416471B1 (en) 1999-04-15 2002-07-09 Nexan Limited Portable remote patient telemonitoring system
DE10316583A1 (de) 2003-04-10 2004-10-28 B.R.A.H.M.S Aktiengesellschaft Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
DE102006060112A1 (de) 2006-12-20 2008-06-26 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM
DE102007022367A1 (de) 2007-05-07 2008-11-20 B.R.A.H.M.S Ag Verfahren zur Bestimmung von aminoterminalen pro-ANP bei übergewichtigen Patienten
EP2107377A1 (en) * 2008-04-04 2009-10-07 BRAHMS Aktiengesellschaft Pro-endothelin-1 levels for the prediction of risk of tachyarrhytmic events
CN105044349B (zh) * 2010-08-26 2018-04-06 弗·哈夫曼-拉罗切有限公司 生物标志物在评估从动脉高血压向心力衰竭的早期转变中的用途
CN108931658A (zh) * 2018-04-16 2018-12-04 上海交通大学医学院附属瑞金医院 用于诊断心力衰竭合并症及预后评估的血清标记物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KOEHLER FRIEDRICH ET AL: "Telemedicine in heart failure: Pre-specified and exploratory subgroup analyses from the TIM-HF trial", INTERNATIONAL JOURNAL OF CARDIOLOGY, vol. 161, no. 3, 2012, pages 143 - 150 *

Also Published As

Publication number Publication date
CA3281050A1 (en) 2026-03-02
CN113348368A (zh) 2021-09-03
US20220260589A1 (en) 2022-08-18
CA3281038A1 (en) 2026-03-02
JP7575400B2 (ja) 2024-10-29
AU2020253042A1 (en) 2021-06-17
BR112021019479A2 (pt) 2021-11-30
CA3124744A1 (en) 2020-10-08
US20250369987A1 (en) 2025-12-04
JP2025015545A (ja) 2025-01-30
WO2020201078A1 (en) 2020-10-08
US12442825B2 (en) 2025-10-14
JP2022526507A (ja) 2022-05-25
EP3948301A1 (en) 2022-02-09

Similar Documents

Publication Publication Date Title
US20250369987A1 (en) Prescription of remote patient management based on biomarkers
Frank Peacock et al. Short‐term mortality risk in emergency department acute heart failure
McCarthy et al. Soluble ST2 in heart failure
Gunsolus et al. Renal dysfunction influences the diagnostic and prognostic performance of high-sensitivity cardiac troponin I
JP6788050B2 (ja) 主要有害心イベントのリスクを予測する方法
Bayés-Genís et al. N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction
Potocki et al. Comparison of midregional pro‐atrial natriuretic peptide with N‐terminal pro‐B‐type natriuretic peptide in the diagnosis of heart failure
EP2386860A2 (en) Predicting mortality and detecting severe disease
Patton et al. N-terminal pro-B-type natriuretic peptide is associated with sudden cardiac death risk: the Cardiovascular Health Study
JP5711131B2 (ja) 最初の有害事象の予測のためのバイオマーカー
Savic‐Radojevic et al. The role of serum VCAM‐1 and TNF‐α as predictors of mortality and morbidity in patients with chronic heart failure
Iqbal et al. Novel biomarkers for heart failure
Karakas et al. Copeptin does not add diagnostic information to high-sensitivity troponin T in low-to intermediate-risk patients with acute chest pain: results from the rule out myocardial infarction by computed tomography (ROMICAT) study
Molvin et al. Cardiovascular biomarkers predict post-discharge re-hospitalization risk and mortality among Swedish heart failure patients
Collinson et al. The clinical and diagnostic performance characteristics of the high sensitivity Abbott cardiac troponin I assay
Prickett et al. C-type natriuretic peptides in coronary disease
Dries et al. Simultaneous assessment of unprocessed ProBNP1-108 in addition to processed BNP32 improves identification of high-risk ambulatory patients with heart failure
Gruson et al. The multidimensional value of natriuretic peptides in heart failure, integrating laboratory and clinical aspects
Meune et al. Utility of 14 novel biomarkers in patients with acute chest pain and undetectable levels of conventional cardiac troponin
EP3715851A1 (en) Prescription of remote patient management based on biomarkers
Palicka Plasma interleukin-6 level is associated with NT-proBNP level and predicts short-and long term mortality in patients with acute heart failure
Hammer et al. Soluble suppression of tumorigenesis-2 is a strong predictor of all-cause, cardiovascular and infection-related mortality risk in haemodialysis patients with diabetes mellitus
Bernelin et al. Neprilysin levels at the acute phase of ST‐elevation myocardial infarction
Adamu et al. Clinical characteristics and outcomes of adults with acute heart failure in a South African teaching hospital
RU2822013C2 (ru) Назначение дистанционного ведения пациентов на основе биомаркеров

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)